PEGylated Poly Propylene Imine Research Articles

SYNTHESIS AND CHARACTERIZATION OF LIGAND ANCHORED POLY PROPYLENEIMINEDENDRIMERS FOR THE TREATMENT OF BRAIN GLIOMA

The goal of this study was to develop and characterize Angiopep-2 attached PEGylated Polypropylene imine (PPI) dendrimers for Temozolomide administration to brain gliomas. For surface neutralisation, synthesized PPI dendrimers were conjugated with PEG-2000. PEGylated PPI dendrimers were further coupled with Angiopep-2 (ANG-PEG-PPP) for enhanced medication transport across the blood-brain barrier (BBB) into the area of the brain tumour. Temozolomide loaded ligand-conjugated PPI dendrimers (TAPP) were characterized for size, % drug loading, cumulative drug release, and cell line studies. The drug loading was found to be 57.42±0.8%. In vitro release profile exhibited an early burst release followed by zero-order kinetics (46.8±0.8% in 24 hours). TAPP dendrimers showed improved antiproliferative efficacy against C6 glioma cells in MTT assays and cellular uptake investigations. The ability of TAPP to target cancer cells was examined using an in vitro co-culture model of BCECs and C6 glioma cells. Our findings suggest that Angiopep-2 coupled PEGylated PPI dendrimers could be a suitable nanocarrier for Temozolomide delivery to brain gliomas.

Imatinib loaded pegylated Poly Propylene Imine dendrimer for delivery to leukemic cells; fabrication of formulation and evaluation

PEGylated polypropyleneimine (PPI) dendritic scaffold was used for the delivery of an anti-leukemic drug, Imatinib. The current study evolves and emerges the use PEGylated PPI dendritic scaffold for the delivery of this drug. In this Imatinib was synthesized and loaded with PEGylated PPI dendritic scaffold. Parameters such as FT-IR, NMR, SEM, drug release, DSC and hemolytictoxicity are required. Other parameters such as drug entrapment of both PEGylated and non-PEGylated systems were comparatively determined. Drug-loading capacity was found to be increased with the PEGylation and reduces the haemolytic toxicity as well as drug release rate. By this, prolonged delivery of Imatinib was found to be suitable with this system. By delivering the drug for a prolonged period of time at a controlled rate, we expect that this approach will improve the management of drug therapy in leukemic patients.

PEGylated dendritic nanoarchitechture improves mean survival time of BDF1 mice bearing myelogenous k -562 leukemia

ObjectiveTo developing and exploring the use of PEGylated poly (propylene imine) dendritic architecture for the delivery of an anti leukemic activity of Prednisolone. MethodsFor this study, PEGylated poly (propylene imine) dendritic architecture was synthesized and loaded with Prednisolone and targeted to the ascetic form of myelogenous leukemia k-562 cellines in hybrid mice BDF1, was used as tumor model. The antileukemic activity was assessed by use of the criterion T/C %, where T was the mean survival time (MST, days) of the drug treated mice, bearing k-562 leukemia and C – the mean survival time (MST, days) of untreated control animals, bearing the same leukemia cellines. ResultsAn antileukemic activity of the studied Prednisolone loaded PEGylated Polypropyleneimine (PPI) dendrimer was found to have increasing the mean survival time of the k-562 myelogenous leukemia cellines bearing BDF1 mice. The criterion “increase of life span” (ILS%) reached maximally 270.1% for the drug loaded dendrimer. ConclusionThe studied dendrimer with Prednisolone showed lower toxicity with improved antileukemic activity in comparison with free Prednisolone. The further experiments in this field are in progress, aiming to design better dendritic formulations, with potential clinical use